KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results. Maetzel A, Smith MD, Duckworth EJ, Hampton SL, et al. J Allergy Clin Immunol 2022;149:2034-2042.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Maetzel A, Smith MD, Duckworth EJ, Hampton SL, et al. KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results. J Allergy Clin Immunol 2022;149:2034-2042.
PMID: 35086692